ChemicalBook
Chinese Japanese Germany Korea

Sunitinib Malate

Anticancer drug Uses
Sunitinib Malate
Sunitinib Malate structure
CAS No.
341031-54-7
Chemical Name:
Sunitinib Malate
Synonyms
SU112248;SU 011248;Malic acid Shu;SUNITINIB MALATE;Sunitinib Mablate;Butanedioic acid, 2;Sunitinib Malate(Sutent);Sunitinib Malate(SU 11248);EZSolution Sunitinib Malate;Sunitinib (SU 11248) Malate
CBNumber:
CB22131216
Molecular Formula:
C22H27FN4O2.C4H6O5
Formula Weight:
532.566
MOL File:
341031-54-7.mol

Sunitinib Malate Properties

Melting point:
189-191°C
storage temp. 
Store at +4°C
solubility 
DMSO: >10mg/mL
form 
powder
InChIKey
XGQXULJHBWKUJY-LYIKAWCPSA-N
CAS DataBase Reference
341031-54-7(CAS DataBase Reference)
SAFETY
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  T
Risk Statements  61-2-48/25-36/37-22-53
Safety Statements  53-22-36/37-24/25
WGK Germany  2
HS Code  29337900
Symbol(GHS):
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H360 May damage fertility or the unborn child Reproductive toxicity Category 1A, 1B Danger
H372 Causes damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 1 Danger P260, P264, P270, P314, P501
Precautionary statements:
P201 Obtain special instructions before use.
P308+P313 IF exposed or concerned: Get medical advice/attention.

Sunitinib Malate price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PZ0012 Sunitinib malate ≥98% (HPLC) 341031-54-7 5mg $112 2018-11-13 Buy
Sigma-Aldrich PZ0012 Sunitinib malate ≥98% (HPLC) 341031-54-7 25mg $443 2018-11-13 Buy
Cayman Chemical 13159 Sunitinib Malate ≥98% 341031-54-7 1mg $30 2018-11-13 Buy
Cayman Chemical 13159 Sunitinib Malate ≥98% 341031-54-7 5mg $58 2018-11-13 Buy
Cayman Chemical 13159 Sunitinib Malate ≥98% 341031-54-7 10mg $95 2018-11-13 Buy

Sunitinib Malate Chemical Properties,Uses,Production

Anticancer drug

Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Uses

Anti-cancer drugs

Chemical Properties

Yellow Solid

Uses

Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

Uses

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit

Uses

A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.

brand name

(Pfizer).

General Description

Sunitinib is available in 12.5-, 25-, and 50-mg capsules fororal administration for the treatment of advanced RCC andGIST upon the failure of imatinib. The agent is a multikinaseinhibitor and has been shown to inhibit PDGF-R,VEGF-R, Kit, RET, and the colony-stimulating factor receptor(CSR-1R). The result of this spectrum of activity isa slowing of tumor progression and inhibition of angiogenesisboth of which are useful in the highly vascularizedcancers, RCC and GIST. The median TTP (time to tumorprogression) was 27.3 weeks for sunitinib and 6.4 weeks with a median time of 24.1 weeks for sunitinib and 6 weeksfor placebo. The agent is well absorbed upon oral administration,and both the parent and major metabolite are highly(90%–95%) protein bound. Metabolism is mediated primarilyby CYP3A4 to give the N-desethyl derivative, which isthe major metabolite (23%–37%), equally active with theparent and undergoes further metabolism by CYP3A4. Theterminal elimination half-life for the parent and N-desethylderivative are 40 to 60 hours and 80 to 110 hours, respectively.Elimination occurs primarily via the feces. Commonadverse effects of sunitinib include fatigue, diarrhea, yellowskin discoloration, anorexia, nausea, and mucositis.Mild myelosuppression has been reported in patients withGIST including neutropenia, lymphopenia, thrombocytopenia,and anemia. There have been reports of cardiotoxicityincluding decreases in left ventricular ejectionfraction, which occurred in 11% of patients during a GISTstudy.

Biological Activity

Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Sunitinib Malate Preparation Products And Raw materials

Raw materials

Preparation Products


Sunitinib Malate Suppliers

Global( 197)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1529 55
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 sales@frappschem.com China 886 50
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3202 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21909 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20675 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32451 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24195 60
Anqing Chico Pharmaceutical Co., Ltd.
15380796838
chloewu@chicopharm.cn CHINA 209 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 25795 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 955 58

View Lastest Price from Sunitinib Malate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-16 Sunitinib Malate
341031-54-7
US $1.00 / KG 1KG 98% 500kg career henan chemical co

341031-54-7(Sunitinib Malate)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved